MedTrace Logo

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

NCT04237649 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2025-05-18

No results posted yet for this study

Summary

The primary objective of the trial was to characterize the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose (RD) for expansion of single agent KAZ954 and KAZ954 in combination with PDR001, NIR178 and NZV930.

Conditions

Interventions

DRUG

KAZ954

KAZ954 will be administered in every arm.

DRUG

PDR001

KAZ954 + PDR001

DRUG

NIR178

KAZ954 + NIR178

DRUG

NZV930

KAZ954 + NZV930

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-20
Primary Completion
2023-09-15
Completion
2023-09-15
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Hong Kong
  • Italy
  • Japan
  • Singapore
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04237649 on ClinicalTrials.gov